Department of Pharmacy, Uppsala Drug Optimization and Pharmaceutical Profiling (UDOPP), Uppsala University, SE-75123 Uppsala, Sweden.
Department of Pharmacy, Uppsala Drug Optimization and Pharmaceutical Profiling (UDOPP), Uppsala University, SE-75123 Uppsala, Sweden; Department of Pharmacy, SciLifeLab Drug Discovery and Development Platform, Uppsala University, SE-75123 Uppsala, Sweden.
J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Aug 1;1205:123340. doi: 10.1016/j.jchromb.2022.123340. Epub 2022 Jun 16.
The majority of women have health problems that require medication after giving birth. Complications such as allergies, postpartum depression, and diabetes are often treated with drugs such as cetirizine, venlafaxine, and metformin, respectively. These treatments are considered safe during lactation, but information of the transfer of drugs to breast milk and possible effects on the infant is scarce. Therefore, this needs to be systematically investigated in larger populations. To enable the determination of drug transfer, we here describe the validation of two rapid, sensitive, and high-throughput analysis methods for 1) simultaneous quantification of cetirizine, venlafaxine, and O-desmethylvenlafaxine in human breast milk, and 2) metformin in human breast milk and plasma. In both methods, a simple protein precipitation protocol with acetonitrile and benchtop-centrifugation was used prior to compound analysis with liquid-chromatography tandem mass spectrometry. The methods had linear ranges between 0.39 - 194.5 ng/mL for cetirizine, 0.28 - 138.7 ng/mL for venlafaxine, 0.26 - 131.7 ng/mL for O-desmethylvenlafaxine, in milk, and 0.65 - 193.7 ng/mL for metformin in both milk and plasma. Intra-run and inter-run precision and accuracy were ≤ 9% for cetirizine, venlafaxine, and O-desmethylvenlafaxine in milk, and ≤ 7% for metformin in milk and plasma. Cetirizine was measured to median milk concentrations of 13 ng/mL (range: 0.65 - 65 ng/mL) in 228 donor samples from breast-feeding women.
大多数女性在分娩后都有需要药物治疗的健康问题。过敏、产后抑郁症和糖尿病等并发症通常分别用西替利嗪、文拉法辛和二甲双胍等药物治疗。这些治疗方法在哺乳期被认为是安全的,但关于药物向母乳转移以及对婴儿可能产生的影响的信息很少。因此,需要在更大的人群中进行系统研究。为了能够确定药物的转移情况,我们在这里描述了两种快速、灵敏、高通量的分析方法的验证,用于 1)同时定量检测人乳中的西替利嗪、文拉法辛和 O-去甲文拉法辛,2)人乳和血浆中的二甲双胍。在这两种方法中,均采用乙腈简单的蛋白沉淀法和台式离心机,然后用液质联用进行化合物分析。方法的线性范围为:在乳中,西替利嗪为 0.39-194.5ng/mL,文拉法辛为 0.28-138.7ng/mL,O-去甲文拉法辛为 0.26-131.7ng/mL;在乳和血浆中,二甲双胍为 0.65-193.7ng/mL。在乳中,西替利嗪、文拉法辛和 O-去甲文拉法辛的日内和日间精密度和准确度均≤9%,乳和血浆中二甲双胍的精密度和准确度均≤7%。在 228 名母乳喂养妇女的供体样本中,西替利嗪的中位乳汁浓度为 13ng/mL(范围:0.65-65ng/mL)。